Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/103808
Title: | Targeting p53 for Melanoma Treatment: Counteracting Tumour Proliferation, Dissemination and Therapeutic Resistance | Authors: | Loureiro, Joana B. Raimundo, Liliana Calheiros, Juliana Carvalho, Carla Barcherini, Valentina Lima, Nuno R. Gomes, Célia Almeida, Maria Inês Alves, Marco G. Costa, José Luís Santos, Maria M. M. Saraiva, Lucília |
Keywords: | melanoma; metastasis; drug resistance; targeted therapy; p53; tryptophanol-derived oxazoloisoindolinone | Issue Date: | 1-Apr-2021 | Publisher: | MDPI AG | Project: | UID/QUI/50006/2020 | Serial title, monograph or event: | Cancers | Volume: | 13 | Issue: | 7 | Abstract: | Melanoma is the deadliest form of skin cancer, primarily due to its high metastatic propensity and therapeutic resistance in advanced stages. The frequent inactivation of the p53 tumour suppressor protein in melanomagenesis may predict promising outcomes for p53 activators in melanoma therapy. Herein, we aimed to investigate the antitumor potential of the p53-activating agent SLMP53-2 against melanoma. Two- and three-dimensional cell cultures and xenograft mouse models were used to unveil the antitumor activity and the underlying molecular mechanism of SLMP53-2 in melanoma. SLMP53-2 inhibited the growth of human melanoma cells in a p53-dependent manner through induction of cell cycle arrest and apoptosis. Notably, SLMP53-2 induced p53 stabilization by disrupting the p53-MDM2 interaction, enhancing p53 transcriptional activity. It also promoted the expression of p53-regulated microRNAs (miRNAs), including miR-145 and miR-23a. Moreover, it displayed anti-invasive and antimigratory properties in melanoma cells by inhibiting the epithelial-to-mesenchymal transition (EMT), angiogenesis and extracellular lactate production. Importantly, SLMP53-2 did not induce resistance in melanoma cells. Additionally, it synergized with vemurafenib, dacarbazine and cisplatin, and resensitized vemurafenib-resistant cells. SLMP53-2 also exhibited antitumor activity in human melanoma xenograft mouse models by repressing cell proliferation and EMT while stimulating apoptosis. This work discloses the p53-activating agent SLMP53-2 which has promising therapeutic potential in advanced melanoma, either as a single agent or in combination therapy. By targeting p53, SLMP53-2 may counteract major features of melanoma aggressiveness. | URI: | https://hdl.handle.net/10316/103808 | ISSN: | 2072-6694 | DOI: | 10.3390/cancers13071648 | Rights: | openAccess |
Appears in Collections: | I&D ICBR - Artigos em Revistas Internacionais I&D CIBB - Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Targeting-p53-for-melanoma-treatment-Counteracting-tumour-proliferation-dissemination-and-therapeutic-resistanceCancers.pdf | 48.16 MB | Adobe PDF | View/Open |
SCOPUSTM
Citations
13
checked on Oct 7, 2024
WEB OF SCIENCETM
Citations
10
checked on Oct 2, 2024
Page view(s)
90
checked on Oct 9, 2024
Download(s)
39
checked on Oct 9, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License